Země: Spojené státy
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
SUCRALFATE (UNII: XX73205DH5) (SUCRALFATE - UNII:XX73205DH5)
Aphena Pharma Solutions - Tennessee, LLC
SUCRALFATE
SUCRALFATE 1 g
ORAL
PRESCRIPTION DRUG
Sucralfate is indicated in: - Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. There are no known contraindications to the use of sucralfate.
Repackaged by Aphena Pharma Solutions - TN. See Repackaging Information for available configurations. Sucralfate 1-g tablets are supplied in bottles of 90, 100, 360 and 500. Light blue, scored, oblong tablets are engraved WATSON 780 on one side and are blank with bisect on the other. Prescribing Information as of June 2008A Manufactured for: Watson Laboratories, Inc. Corona, CA 92880 USA Manufactured by: sanofi-aventis U.S. LLC Kansas City, MO 64137 USA 50088983
New Drug Application
SUCRALFATE- SUCRALFATE TABLET APHENA PHARMA SOLUTIONS - TENNESSEE, LLC ---------- PRESCRIBING INFORMATION AS OF JUNE 2008A SUCRALFATE TABLETS RX ONLY DESCRIPTION Sucralfate is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. Tablets for oral administration contain 1 g of sucralfate. Also contain: FD&C Blue #1 Lake, magnesium stearate, microcrystalline cellulose, and starch. Therapeutic category: antiulcer. CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent: Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. In vitro, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%. In vitro, sucralfate adsorbs bile salts. These observations suggest that sucralfate’s antiulcer activity is the result of formation of an ulcer- adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14-16 mEq of acid-neutralizing capacity per 1-g dose of sucralfate. CLINICAL TRIALS ACUTE DUODENAL ULCER Over 600 patients have participated in well-controlled clinical trials worldwide. Multicenter trials conducted in the United States, both of them placebo-controlled studies with endoscopic evaluation at 2 and 4 weeks,showed: STUDY 1 TREATMENT GROUPS ULCER HEALING/ NO. PATIENTS 2 WK 4 WK (OVERALL) Sucralfate 37/105 (35.2%) 82/109 (75.2%) Placebo 26/106 (24.5%) 68/107 ( Přečtěte si celý dokument